The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Eisai; Lilly; Merck; Pfizer; Roche; Seagen
IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC).
 
Rebecca Dent
No Relationships to Disclose
 
Sung-Bae Kim
Research Funding - Dongkook (Inst); Novartis (Inst); Samyang (Inst); Sanofi (Inst)
 
Mafalda Oliveira
Consulting or Advisory Role - Roche/Genentech
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst)
 
Steven J. Isakoff
Consulting or Advisory Role - Abbvie; Genentech/Roche; PharmaMar
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Merck (Inst); OncoPep (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Carlos H. Barrios
Honoraria - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech
Research Funding - AB Science; Abbvie; Abraxis BioScience; Amgen; Asana Biosciences; Astellas Pharma; AstraZeneca; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo; Exelixis; GlaxoSmithKline; GlaxoSmithKline; ImClone Systems; LEO Pharma; Lilly; Medivation; Merck; Merrimack; Millennium; Mylan; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Arno Therapeutics; AstraZeneca; Celgene; Eisai; Genentech/Roche; Lilly; Nektar; Novartis; Pfizer
Consulting or Advisory Role - Abbvie; Arno Therapeutics; AstraZeneca; Celgene; Eisai; Genentech/Roche; Lilly; Nektar; Novartis; Pfizer
Travel, Accommodations, Expenses - Abbvie; Celgene; Lilly; Nektar; Novartis; Pfizer
 
Xuyang Lu
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
 
Matthew Wongchenko
Employment - Genentech/Roche
Stock and Other Ownership Interests - ARIAD; Genentech/Roche
 
Denise Bradley
Employment - Roche
Patents, Royalties, Other Intellectual Property - Roche
 
Aruna Mani
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Research Funding - EMD Serono (Inst); Oncothyreon (Inst)
 
Jose Baselga
Leadership - Infinity Pharmaceuticals; Varian Medical Systems
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems
Consulting or Advisory Role - GRAIL; Lilly; Novartis
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Puma Biotechnology; Roche; Synthon; Tesaro
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Inivata (Inst); Pfizer (Inst); Roche (Inst)